Contineum Therapeutics
CTNM
49 hedge funds and large institutions have $229M invested in Contineum Therapeutics in 2024 Q2 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
68.54% more ownership
Funds ownership: 0% → 68.54% (+69%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$33.1M |
| 2 |
JJ
Johnson & Johnson
New Brunswick,
New Jersey
|
+$31.9M |
| 3 |
PA
Perceptive Advisors
New York
|
+$25.2M |
| 4 |
VVM
Versant Venture Management
San Francisco,
California
|
+$14.8M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$12.9M |
Top Sellers
CTNM Hedge Fund Activity: Q2 2024 in Review
49 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q2 2024, worth a combined $229M.
Buyers outnumbered sellers: 49 funds opened new CTNM positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $33.1M.
- 49 institutional investors held Contineum Therapeutics (CTNM) as of Q2 2024, up from 0 in Q1 2024.
- Funds reported $229M of Contineum Therapeutics stock for Q2 2024.
- 49 funds opened new Contineum Therapeutics positions in Q2 2024 and 0 closed out, a net change of +49 holders.
- The largest Contineum Therapeutics buyer in Q2 2024 was Suvretta Capital Management, an estimated $33.1M added.
Based on aggregated 13F filings for Q2 2024.